Switch theme
Sign up to access all valuation multiples
Poxel SA is a biopharmaceutical company. It is focused on the development of novel treatments for metabolic diseases, including type 2 diabetes and liver diseases, such as nonalcoholic steatohepatitis (NASH) and rare disorders (ALD/AMN). It has developed a portfolio of drug candidates, including its candidates: Imeglimin, for the treatment of type 2 diabetes, and PXL770 and PXL065, for the treatment of NASH.
2009
37
LTM Revenue $7.1M
LTM EBITDA n/a
$74.7M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Poxel has a last 12-month revenue of $7.1M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Poxel achieved revenue of $2.1M and an EBITDA of -$13.1M.
Poxel expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Poxel valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $2.1M | $7.1M | XXX | XXX | XXX |
| Gross Profit | $14.3M | $2K | XXX | XXX | XXX |
| Gross Margin | 673% | 0% | XXX | XXX | XXX |
| EBITDA | -$13.1M | n/a | XXX | XXX | XXX |
| EBITDA Margin | -614% | NaN% | XXX | XXX | XXX |
| Net Profit | -$25.5M | -$33.7M | XXX | XXX | XXX |
| Net Margin | -1200% | -473% | XXX | XXX | XXX |
| Net Debt | $1.5M | $31.4M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Poxel's stock price is EUR 0 (or $0).
Poxel has current market cap of EUR 24.7M (or $26.5M), and EV of EUR 69.5M (or $74.7M).
See Poxel trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $74.7M | $26.5M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Poxel has market cap of $26.5M and EV of $74.7M.
Poxel's trades at 10.5x LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Poxel's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Poxel and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $74.7M | XXX | XXX | XXX |
| EV/Revenue | 10.5x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpPoxel's NTM/LTM revenue growth is -100%
Poxel's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $0.8M for the same period.
Over next 12 months, Poxel's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Poxel's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Poxel and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 235% | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.8M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 254% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 1058% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 1452% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Poxel acquired XXX companies to date.
Last acquisition by Poxel was XXXXXXXX, XXXXX XXXXX XXXXXX . Poxel acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Poxel founded? | Poxel was founded in 2009. |
| Where is Poxel headquartered? | Poxel is headquartered in France. |
| How many employees does Poxel have? | As of today, Poxel has 37 employees. |
| Who is the CEO of Poxel? | Poxel's CEO is Mr. Thomas Kuhn. |
| Is Poxel publicy listed? | Yes, Poxel is a public company listed on PAR. |
| What is the stock symbol of Poxel? | Poxel trades under POXEL ticker. |
| When did Poxel go public? | Poxel went public in 2015. |
| Who are competitors of Poxel? | Similar companies to Poxel include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Poxel? | Poxel's current market cap is $26.5M |
| What is the current revenue of Poxel? | Poxel's last 12-month revenue is $7.1M. |
| What is the current EV/Revenue multiple of Poxel? | Current revenue multiple of Poxel is 10.5x. |
| What is the current revenue growth of Poxel? | Poxel revenue growth between 2023 and 2024 was 235%. |
| Is Poxel profitable? | Yes, Poxel is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
